Substantial improvement observed through month 12, which persisted through month 60, but lessened with fewer treatments
Your search for bevacizumab returned 14 results
Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.
The approval was based on data from the SORAYA trial.
High drug prices and ongoing shortages may prompt cancer patients to buy treatments online and fall prey to illegitimate pharmacies.